Results 221 to 230 of about 7,511,780 (403)

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care

open access: yesNature Network Boston, 2018
M. Komorowski   +4 more
semanticscholar   +1 more source

Quantitative Shape Irregularity and Density Heterogeneity Predict Hematoma Expansion in Patients With Intracerebral Hemorrhage

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose This study aimed to explore the association between quantitative shape irregularity and density heterogeneity of hematomas and hematoma expansion (HE) for intracerebral hemorrhage (ICH) patients. Methods This cohort study included patients arriving within 24 h of symptom onset between August 2021 and July 2022 as the derivation cohort ...
Zeqiang Ji   +11 more
wiley   +1 more source

Exploring if Longitudinal Changes on PET Imaging Can Serve as a Biomarker for Stiff Person Syndrome Spectrum Disorders

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify metabolic patterns in the brain and musculoskeletal system of stiff person syndrome spectrum disorders (SPSD) patients over time using PET imaging and evaluate the impact of immune therapy on metabolic activity as a surrogate for treatment response.
Munther M. Queisi   +4 more
wiley   +1 more source

Volatile anesthetics in the intensive care unit. [PDF]

open access: yesAnaesthesiol Intensive Ther
Morrison-Nozik A, Wąsowicz M.
europepmc   +1 more source

Home - About - Disclaimer - Privacy